NVS Novartis AG

  1. Stocks
  2. Healthcare
  3. NYSE: NVS

Price (delayed)

$154.835

Market cap

$294.3B

P/E Ratio

23.25

Dividend/share

$4.77

EPS

$6.66

Enterprise value

$335.7B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 92

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the ...

Highlights
The quick ratio is up by 8% year-on-year and by 6% since the previous quarter
The company's equity rose by 8% QoQ
The company's debt has surged by 50% YoY and by 4.3% QoQ
The stock's P/E is 34% more than its 5-year quarterly average of 17.5 and 14% more than its last 4 quarters average of 20.5
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.novartis.com
Peers: PFE MRK JNJ TEVA

Key stats

What are the main financial stats of NVS

NVS stock price

How has the Novartis AG stock price performed over time
Intraday
-0.84%
1 week
-0.82%
1 month
-3.17%
1 year
34.29%
YTD
12.31%
QTD
-1.2%

Financial performance

How have Novartis AG's revenue and profit performed over time
Revenue
$56.69B
Gross profit
$42.37B
Operating income
$17.1B
Net income
$12.76B
Gross margin
74.7%
Net margin
22.5%
The company's net margin fell by 9% YoY and by 6% QoQ
The company's net income fell by 7% YoY and by 6% QoQ
Novartis AG's revenue has increased by 2.7% YoY
NVS's operating income is up by 2.5% year-on-year

Price vs fundamentals

How does NVS's price correlate with its fundamentals

Growth

What is Novartis AG's growth rate over time

Valuation

What is Novartis AG stock price valuation
NVS P/E details
P/E
23.25
P/B
7.11
P/S
5.2
EV/EBIT
19.84
EV/EBITDA
11.84
EV/Sales
5.92
The stock's P/E is 34% more than its 5-year quarterly average of 17.5 and 14% more than its last 4 quarters average of 20.5
The company's EPS fell by 5% QoQ and by 3.5% YoY
NVS's P/B is 53% above its 5-year quarterly average of 4.7 and 10% above its last 4 quarters average of 6.5
The company's equity rose by 8% QoQ
The P/S is 17% more than the 5-year quarterly average of 4.5 and 7% more than the last 4 quarters average of 4.9
Novartis AG's revenue has increased by 2.7% YoY

Efficiency

How efficient is Novartis AG business performance
The ROIC has declined by 23% year-on-year and by 9% since the previous quarter
Novartis AG's ROA has decreased by 17% YoY and by 10% from the previous quarter
NVS's ROE is down by 8% YoY and by 6% QoQ

Dividends

What is NVS's dividend history
Dividend details
DPS
$4.77
Dividend yield
3.08%
Payout ratio
71.7%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Novartis AG financials performed over time
NVS's total assets is 52% greater than its total liabilities
NVS's total liabilities is up by 28% year-on-year
NVS's total assets is up by 17% year-on-year and by 3% since the previous quarter
The company's debt is 18% higher than its equity
The debt to equity has soared by 51% YoY but it has contracted by 3.3% from the previous quarter
The company's debt has surged by 50% YoY and by 4.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.